Skip to main navigation Skip to search Skip to main content

Identification of potential prognostic and predictive immunological biomarkers in patients with stage i and stage iii non‐small cell lung cancer (Nsclc): A prospective exploratory study

  • Rianne D.W. Vaes*
  • , Kobe Reynders
  • , Jenny Sprooten
  • , Kathleen T. Nevola
  • , Kasper M.A. Rouschop
  • , Marc Vooijs
  • , Abhishek D. Garg
  • , Maarten Lambrecht
  • , Lizza E.L. Hendriks
  • , Marijana Rucevic
  • , Dirk De Ruysscher
  • *Corresponding author for this work
  • Maastricht University
  • KU Leuven
  • OLINK Proteomics Inc.
  • University Hospitals Leuven

Research output: Contribution to journal › Article › Academic › peer-review

35 Citations (Scopus)
60 Downloads (Pure)

Abstract

Radiotherapy (RT) and chemotherapy can induce immune responses, but not much is known regarding treatment‐induced immune changes in patients. This exploratory study aimed to identify potential prognostic and predictive immune‐related proteins associated with progression-free survival (PFS) in patients with non‐small cell lung cancer (NSCLC). In this prospective study, patients with stage I NSCLC treated with stereotactic body radiation therapy (n = 26) and patients with stage III NSCLC treated with concurrent chemoradiotherapy (n = 18) were included. Blood samples were collected before (v1), during (v2), and after RT (v3). In patients with stage I NSCLC, CD244 (HR: 10.2, 95% CI: 1.8–57.4) was identified as a negative prognostic biomarker. In patients with stage III NSCLC, CR2 and IFNGR2 were identified as positive prognostic biomarkers (CR2, HR: 0.00, 95% CI: 0.00–0.12; IFNGR2, HR: 0.04, 95% CI: 0.00–0.46). In addition, analysis of the treatment‐induced changes of circulating protein levels over time (Δv2/v3−v1) also identified CXCL10 and IL‐10 as negative predictive biomarkers (CXCL10, HR: 3.86, 95% CI: 1.0–14.7; IL‐10, HR: 16.92 (2.74–104.36)), although serum‐induced interferon (IFN) response was a positive prognostic. In conclusion, we identified several circulating immunogenic proteins that are correlated with PFS in patients with stage I and stage III NSCLC before and during treatment.

Original languageEnglish
Article number6259
JournalCancers
Volume13
Issue number24
DOIs
Publication statusPublished - 13 Dec 2021
Externally publishedYes

Bibliographical note

Funding Information:
This research received no external funding. ADG received research funding from Research Foundation Flanders (FWO) (Fundamental Research Grant, G0B4620N and Excellence of Science/EOS grant, 30837538, for “DECODE” consortium) and KU Leuven (C1 grant, C14/19/098, C3 grant, C3/21/037, and POR award funds, POR/16/040).

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Identification of potential prognostic and predictive immunological biomarkers in patients with stage i and stage iii non‐small cell lung cancer (Nsclc): A prospective exploratory study'. Together they form a unique fingerprint.

Cite this